Progestin megestrol acetate treatment of 160 postmenopausal women with progressive metastatic breast cancer is evaluated. Objective remission was found in 48 patients (30%) and stabilization of disease occurred in 58 (36%) cases. In each of these response categories, the median time interval before subsequent progression took place was nine months. Patients with a postmenopausal age of more than five years showed a significantly higher remission rate than did younger patients. In addition, great differences in remission rates were apparent between groups of patients classified according to dominant sites and separate sites of lesions. The length of disease-free interval did not prove to be of great importance in predicting the remission. No great difference in remission rates were found between patients treated with megestrol acetate as the first hormonal treatment and those previously treated with hormones. Side effects were negligible; a moderate weight increase without demonstrated fluid retention was found during therapy in 10% of the cases. Toxicity was not encountered. Megestrol acetate therapy may be the first choice of treatment in late postmenopausal patients with soft tissue and lung metastases.

Download full-text PDF

Source
http://dx.doi.org/10.1002/1097-0142(19801201)46:11<2369::aid-cncr2820461111>3.0.co;2-3DOI Listing

Publication Analysis

Top Keywords

megestrol acetate
12
breast cancer
8
remission rates
8
patients
6
remission
5
progestin therapy
4
therapy advanced
4
advanced breast
4
megestrol
4
cancer megestrol
4

Similar Publications

Meningioma regression after progestin treatment interruption is already established. Zoely is a combined oral contraceptive including oestradiol and progestin (nomegestrol acetate). The effect of combined oestrogen with nomegestrol acetate on meningioma is currently unknown.

View Article and Find Full Text PDF

Purpose Of Review: Endometrial cancer (EC) is rising in incidence, particularly in younger, premenopausal women, due to increasing rates of obesity and delayed childbearing. This review evaluates current and emerging endocrine therapies, with a focus on fertility-preserving approaches for early-stage EC and treatment options for advanced or recurrent disease.

Recent Findings: Fertility-sparing endocrine therapies, such as medroxyprogesterone acetate, megestrol acetate, and levonorgestrel-releasing intrauterine devices, achieve high response rates but carry recurrence risks.

View Article and Find Full Text PDF

Purpose: The CDK4/6 inhibitor palbociclib inhibits cyclin A, which is overexpressed in endometrial cancer. Combining palbociclib with endocrine therapy improves efficacy in hormone receptor-positive breast cancer. We investigated palbociclib combined with endocrine therapy for estrogen receptor-positive advanced/recurrent endometrial cancer.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to assess the effectiveness of combining medroxyprogesterone acetate (MA) and metformin as a fertility-sparing treatment for atypical endometrial hyperplasia (AEH) and early-stage endometrial adenocarcinoma (G1 EAC).
  • It involved 60 patients who were divided into two groups, one receiving only MA and the other receiving MA plus metformin, with both treatments monitored for up to 12 months through regular follow-ups.
  • Results showed similar complete response rates for both treatments, but the combined group had no significant weight gain compared to the group taking MA alone, and it led to favorable changes in certain endometrial biomarkers.
View Article and Find Full Text PDF

Background: Cervical cancer is one of the most common malignancies among women. Vesicle-mediated transport mechanisms significantly influence tumor cell behavior through intercellular material exchange. However, prognostic significance in CC patients remains underexplored.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!